Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-11-26 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the receipt of clinical trial approval for a new drug (JMT206) in China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company business developments that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-26 English
VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the U.S. FDA approval for clinical trials of a new drug (SYH2061 Injection). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company business developments that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-24 English
VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug (SYH2056). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company business activities (clinical trial approval) that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-21 English
APPOINTMENT OF AN EXECUTIVE DIRECTOR
Board/Management Information Classification · 1% confidence The document is an official announcement from CSPC Pharmaceutical Group Limited regarding the appointment of Mr. QU Zhiyong as an Executive Director. It details his biographical information, service contract terms, and shareholdings. This falls directly under the category of board or management changes.
2025-11-21 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 1% confidence The document is titled 'LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION' and provides a breakdown of the Board of Directors, their executive/non-executive status, and their committee memberships. This type of disclosure is a standard corporate governance filing detailing board composition and committee structure, which falls under the Governance Information category.
2025-11-21 English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Results' announcement for CSPC Pharmaceutical Group Limited for the nine months ended 30 September 2025. It contains detailed financial highlights, revenue breakdowns, profit analysis, and a comprehensive business review including R&D updates. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). 9M 2025
2025-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.